Worth reading
68In focus
Scored from 3 of 6 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
-1583
¥ millions (year-on-year change in operating income)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Earnings presentation materialsThird quarter of the fiscal year ending December 20267 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥22 million
Operating profit¥-3,916 million
Net income¥-4,527 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in Selling, General and Administrative Expenses¥-282 million
- Increase in R&D Expenses¥-1,342 million
- Increase in financial revenue¥507 million
- Decrease in financial expenses¥1,028 million
- Increase in gains on valuation of securities¥1,169 million
- Decrease in losses on valuation of derivatives¥1,732 million
New initiatives
- Change of the commercial manufacturing site to Minaris's Yokohama facility
- Development of the KOBE Cell Innovation Center in Kobe (scheduled to begin operations in January 2028)
- Expansion of cGMP manufacturing CDMO services
- Supply agreement for conditioned medium with JENECELL
- Formulation of a new Vision, Mission and Philosophy
Key KPIsA metric the company considers important as a management benchmark.
- REVIVE-ARDS trial patient count550 Example
- Number of cases in the MATRICS-1 trial156 people
- Annual supply capacity40,000 people/year
- Estimated number of ARDS patients in the United States20,000 People/year
- Trend toward lower mortality among patients with severe pneumonia treated with HLCM05160 %
Unit price and quantity metricsThese figures show sales broken down by price and volume.
- Drug pricing in the United States¥3,000 10,000
- Estimated number of patients in the United States eligible to receive this drug20,000 People/year
- Total number of patients treated from year 5 onward13,000–21,000
Market Size / Share
- Estimated global ARDS patient population1,100,000 People/year
- Estimated ARDS market size in the United States20,000 People/year
- Annual US ARDS sales potential¥4,750 100 million
Orders received and order backlog
¥144 million initial order for conditioned medium
Number of employees
Number of Employees90 people
Change during the periodUp 30 people year on year
| Item | Details |
|---|---|
| Document type | Earnings presentation materials |
| Fiscal Period Covered | Third quarter of the fiscal year ending December 2026 |
| Net Sales | ¥22 million |
| Operating profit | ¥-3,916 million |
| Net income | ¥-4,527 million |
| Breakdown of Factors Affecting the Change | Factors Increase in Selling, General and Administrative Expenses / Amount ¥-282 million, Factors Increase in R&D Expenses / Amount ¥-1,342 million, Factors Increase in financial revenue / Amount ¥507 million, Factors Decrease in financial expenses / Amount ¥1,028 million, Factors Increase in gains on valuation of securities / Amount ¥1,169 million, Factors Decrease in losses on valuation of derivatives / Amount ¥1,732 million |
| Key KPIs | Indicator name REVIVE-ARDS trial patient count / Value 550 Example / Year on year against the same period last year Not disclosed, Indicator name Number of cases in the MATRICS-1 trial / Value 156 people / Year on year against the same period last year Not disclosed, Indicator name Annual supply capacity / Value 40,000 people/year / Year on year against the same period last year Not disclosed, Indicator name Estimated number of ARDS patients in the United States / Value 20,000 People/year / Year on year against the same period last year Not disclosed, Indicator name Trend toward lower mortality among patients with severe pneumonia treated with HLCM051 / Value 60 % / Year on year against the same period last year Not disclosed |
| Unit price and quantity metrics | Indicator name Drug pricing in the United States / Value ¥3,000 10,000, Indicator name Estimated number of patients in the United States eligible to receive this drug / Value 20,000 People/year, Indicator name Total number of patients treated from year 5 onward / Value 13,000–21,000 |
| Number of employees | Number of Employees 90 people / Change during the period Up 30 people year on year |
| Orders received and order backlog | Amount ¥144 million (initial order for conditioned medium) |
| Market Size / Share | Market Estimated global ARDS patient population / Value 1,100,000 People/year, Market Estimated ARDS market size in the United States / Value 20,000 People/year, Market Annual US ARDS sales potential / Value ¥4,750 100 million |
| New initiatives | Change of the commercial manufacturing site to Minaris's Yokohama facility, Development of the KOBE Cell Innovation Center in Kobe (scheduled to begin operations in January 2028), Expansion of cGMP manufacturing CDMO services, Supply agreement for conditioned medium with JENECELL, Formulation of a new Vision, Mission and Philosophy |
Items this document does not state (19)
Ordinary incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company cites increases of ¥282 million in selling, general and administrative expenses and ¥1,342 million in research and development expenses as reasons for the deterioration in operating loss. Regarding net loss, it explains that the ¥507 million increase in financial income and ¥1,028 million decrease in financial costs restrained the expansion of the loss.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.